Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
73 hedge funds and large institutions have $474M invested in Blueprint Medicines in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 9 closing their positions.
9,855% more call options, than puts
Call options by funds: $19.6M | Put options by funds: $197K
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
4% more funds holding
Funds holding: 70 → 73 (+3)
7% less capital invested
Capital invested by funds: $509M → $474M (-$35.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$18.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$13M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.5M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$5.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$17.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.22M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$6.95M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$2.04M |
BPMC Hedge Fund Activity: Q4 2015 in Review
73 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2015, worth a combined $474M — down 6.9% from $509M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BPMC positions and 9 closed out — a net gain of 4 holders — while 29 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $18.1M. The largest seller was Wellington Management Group, cutting an estimated $17.8M.
- 73 institutional investors held Blueprint Medicines (BPMC) as of Q4 2015, up from 70 in Q3 2015.
- Funds reported $474M of Blueprint Medicines stock for Q4 2015, down 6.9% quarter-over-quarter.
- 13 funds opened new Blueprint Medicines positions in Q4 2015 and 9 closed out, a net change of +4 holders.
- The largest Blueprint Medicines buyer in Q4 2015 was Fidelity International, an estimated $18.1M added.
- The largest Blueprint Medicines seller in Q4 2015 was Wellington Management Group, an estimated $17.8M sold.
Based on aggregated 13F filings for Q4 2015.